<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04358471</url>
  </required_header>
  <id_info>
    <org_study_id>HMR-2001</org_study_id>
    <nct_id>NCT04358471</nct_id>
  </id_info>
  <brief_title>Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)</brief_title>
  <official_title>A Phase 2 Multi-Center Trial Evaluating Intravitreal AAVCAGsCD59 Compared to Sham Injection for the Treatment of Advanced Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hemera Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hemera Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with advanced dry AMD with GA meeting inclusion criteria will be randomized in one
      eye in a 1:1:1 ratio comparing intravitreal high or low dose AAVCAGsCD59 with a sham
      injection. All enrolled subjects will be followed for 24 months to evaluate reduction in GA
      growth and safety of intravitreal AAVCAGsCD59.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be assigned to low dose AAVCAGsCD59, high dose AAVCAGsCD59, or sham arm.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the change in Geographic Atrophy area (mm2) measured at Day 0 and compared to the measurement at Month 24</measure>
    <time_frame>24 Months</time_frame>
    <description>Geographic atrophy will be measured based on imaging of the retina</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of conversion from dry to wet age-related macular degeneration</measure>
    <time_frame>24 Months</time_frame>
    <description>Measure the number of treated eyes in the sham and AAVCAGsCD59-treated arms that convert from dry to wet age-related macular degeneration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visual acuity of the AAVCAGsCD59 treated eye</measure>
    <time_frame>24 Months</time_frame>
    <description>Visual acuity measured on an Early Treatment Diabetic Retinopathy Study (ETDRS) chart will be compared at Day 0 and Month 24</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Dry Age-related Macular Degeneration</condition>
  <condition>Geographic Atrophy</condition>
  <condition>Gene Therapy</condition>
  <condition>Intravitreal Injection</condition>
  <arm_group>
    <arm_group_label>Intravitreal AAVCAGsCD59 1.071x10e12 vg Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal AAVACGsCD59 at a dose of 1.071x10e12 vg administered once on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravitreal AAVCAGsCD59 3.56x10e11 vg Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal AAVACGsCD59 at a dose of 3.56x10e11 vg administered once on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Intravitreal Injection</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Intravitreal Sham injection administered once on Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intravitreal AAVCAGsCD59</intervention_name>
    <description>AAVCAGsCD59 is administered as an intravitreal injection in the enrolled eye</description>
    <arm_group_label>Intravitreal AAVCAGsCD59 1.071x10e12 vg Injection</arm_group_label>
    <arm_group_label>Intravitreal AAVCAGsCD59 3.56x10e11 vg Injection</arm_group_label>
    <other_name>HMR59</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intravitreal Sham Injection</intervention_name>
    <description>Sham injection mimics a real injection in the enrolled eye</description>
    <arm_group_label>Sham Intravitreal Injection</arm_group_label>
    <other_name>Sham</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Advanced dry AMD with GA in the study eye

          2. BCVA in the study eye of 80 or less ETDRS letters (Snellen equivalent 20/25 or worse)

          3. Total cumulative GA lesion size 2.5 mm2 to 12.5 mm2 in the study eye as confirmed by
             the reading center during the Screening Period.

        Exclusion Criteria:

          1. GA secondary to non-AMD etiologies in the study eye (i.e. myopia, inherited retinal
             diseases).

          2. GA associated with the presence of an RPE rip.

          3. GA contiguous with peripapillary atrophy.

          4. Active CNV secondary to wet AMD in the study eye and currently receiving anti-VEGF
             ocular treatment within the previous 18 months.

          5. Subretinal fibrosis in the macula from CNV both clinically and imaged on SD-OCT in the
             macula.

          6. Previous macular laser photocoagulation (i.e. focal or grid laser for macular edema),
             photodynamic therapy (PDT), ocular/orbital radiation, laser to CNV, or subretinal
             surgery for CNV in the study eye.

          7. History of conditions in the study eye which might alter visual acuity or interfere
             with study testing including proliferative diabetic retinopathy (PDR), clinically
             significant macular edema (CSME), central retinal vein occlusion (CRVO), hemi retinal
             vein occlusion (HRVO), macular branch retinal vein occlusion, and optic neuropathy.

          8. Active uncontrolled glaucoma with at least one of the following: IOP&gt;30 mmHg despite
             maximum medical treatment with glaucoma medications, cup-to-disc ratio of &gt;0.9, visual
             field defects secondary to glaucoma that involve the macula, or optic atrophy from
             glaucoma.

          9. Active acute or chronic infectious uveitis, retinitis, or conjunctivitis (excluding
             blepharitis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adam Rogers, MD</last_name>
    <phone>857-302-3027</phone>
    <email>arogers@hemerabiosciences.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Siobhan Garbutt, PhD</last_name>
    <phone>919-595-0258</phone>
    <email>siobhan.garbutt@lexitas.com</email>
  </overall_contact_backup>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 22, 2020</study_first_submitted>
  <study_first_submitted_qc>April 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2020</study_first_posted>
  <last_update_submitted>June 21, 2020</last_update_submitted>
  <last_update_submitted_qc>June 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Geographic Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

